Literature DB >> 1291662

Glomerular hypertension: cause and consequence of renal injury.

J R Neuringer1, B M Brenner.   

Abstract

BACKGROUND: Glomerular capillary hyperfiltration and hypertension occur in certain disease states and also in response to a reduction in the number of functional nephrons. Experimental studies have shown that these glomerular hemodynamic changes are maladaptive, and ultimately damaging to the kidney. Amelioration of glomerular hyperfunction by dietary protein restriction or antihypertensive therapy lessens glomerular injury in several experimental models of chronic renal disease. THESIS: Hyperfiltration may similarly occur in humans with diabetes mellitus, a solitary or remnant kidney, or acquired renal disease. There is evidence to suggest that these people may therefore be at increased risk for the development of renal injury. CURRENT RESEARCH: Clinical studies have shown that dietary protein restriction and antihypertensive therapy may beneficially affect the course of chronic renal failure in humans. Large multicenter trials are currently underway on the effects of these therapeutic maneuvers on the progression of chronic renal disease.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1291662

Source DB:  PubMed          Journal:  J Hypertens Suppl        ISSN: 0952-1178


  14 in total

1.  Primary proximal tubule hyperreabsorption and impaired tubular transport counterregulation determine glomerular hyperfiltration in diabetes: a modeling analysis.

Authors:  K Melissa Hallow; Yeshitila Gebremichael; Gabriel Helmlinger; Volker Vallon
Journal:  Am J Physiol Renal Physiol       Date:  2017-02-01

Review 2.  Hyperfiltration-mediated Injury in the Remaining Kidney of a Transplant Donor.

Authors:  Tarak Srivastava; Sundaram Hariharan; Uri S Alon; Ellen T McCarthy; Ram Sharma; Ashraf El-Meanawy; Virginia J Savin; Mukut Sharma
Journal:  Transplantation       Date:  2018-10       Impact factor: 4.939

Review 3.  Glomerular hyperfiltration: definitions, mechanisms and clinical implications.

Authors:  Imed Helal; Godela M Fick-Brosnahan; Berenice Reed-Gitomer; Robert W Schrier
Journal:  Nat Rev Nephrol       Date:  2012-02-21       Impact factor: 28.314

Review 4.  Renal cell carcinoma in pregnancy: a rare coexistence.

Authors:  S Boussios; N Pavlidis
Journal:  Clin Transl Oncol       Date:  2013-09-04       Impact factor: 3.405

5.  Measuring the intrarenal distribution of glomerular volumes from histological sections.

Authors:  Bradley D Hann; Edwin J Baldelomar; Jennifer R Charlton; Kevin M Bennett
Journal:  Am J Physiol Renal Physiol       Date:  2016-03-16

6.  Uteroplacental insufficiency affects kidney VEGF expression in a model of IUGR with compensatory glomerular hypertrophy and hypertension.

Authors:  Mariana Baserga; Allyson L Bares; Merica A Hale; Christopher W Callaway; Robert A McKnight; Pascale H Lane; Robert H Lane
Journal:  Early Hum Dev       Date:  2009-02-01       Impact factor: 2.079

7.  Decreased alpha-adrenergic constriction of renal preglomerular arteries occurs with age and is gender-specific in the rat.

Authors:  Jeff C Falcone; Irving G Joshua; John C Passmore
Journal:  Age (Dordr)       Date:  2005-12-10

8.  Nephron-deficient Fvb mice develop rapidly progressive renal failure and heavy albuminuria involving excess glomerular GLUT1 and VEGF.

Authors:  Youli Wang; Kathleen O Heilig; Andrew W Minto; Shenglin Chen; Minghui Xiang; David A Dean; Richard C Geiger; Anthony Chang; Dimitrina D Pravtcheva; Martin Schlimme; Dilip K Deb; Ying Wang; Charles W Heilig
Journal:  Lab Invest       Date:  2009-11-16       Impact factor: 5.662

9.  A cohort study of reproductive and hormonal factors and renal cell cancer risk in women.

Authors:  G C Kabat; S A Navarro Silvera; A B Miller; T E Rohan
Journal:  Br J Cancer       Date:  2007-02-20       Impact factor: 7.640

10.  Pregnancy and risk of renal cell cancer: a population-based study in Sweden.

Authors:  Mats Lambe; P Lindblad; J Wuu; R Remler; C-c Hsieh
Journal:  Br J Cancer       Date:  2002-05-06       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.